Lilly Endowment Inc, an insider at Eli Lilly and Co (LLY), sold 95,142,778 shares of the company on September 30, 2025, at a price of $832.43 per share. The total transaction value reached approximately $79.2 billion.
Following this sale, Lilly Endowment Inc retains 95,142,778 shares of Eli Lilly. Such transactions often occur for reasons including diversification, tax planning, or personal financial needs. While significant insider selling can draw attention, it does not inherently reflect negative sentiment toward the company.
Eli Lilly, headquartered in Indianapolis, Indiana, is a leading player in the pharmaceuticals industry, employing 47,000 individuals. The company specializes in various therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience. Key products include Humalog, Trulicity, and Jardiance.
With a market capitalization of $992.3 billion, Eli Lilly boasts a P/E ratio of 53.89 and an EPS of 20.45. The company is scheduled to announce its upcoming earnings on April 29, 2026, with an estimated EPS of $7.16 and revenue of $17.1 billion. Investors are encouraged to consider insider activity alongside other fundamental and technical factors for a comprehensive view of the company's performance.